Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for REYOBIQ (Rhenium Re186 Obisbemeda) in Glioblastoma. The expected timing is based on the latest available company guidance and may change.
05/15/26:- ReSPECT-GBM Ph2 data expected Q1 2027. Enrollment completion planned in 2026. SpectronRx added as second GMP site. 08/14/26:- ReSPECT-GBM Ph2 enrollment continues and will complete in 2026. Data is expected Q1 2027, followed by an FDA End-of-Phase 2 meeting.
Verification
Confirm timing and program details against the company announcement or filing.